Guidelines on Testicular Cancer

P. Albers (chairman), W. Albrecht, F. Algaba, C. Bokemeyer, G. Cohn-Cedermark, A. Horwich, M.P. Laguna

© European Association of Urology 2008
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>1</th>
<th>BACKGROUND</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.1</td>
<td>Methods</td>
<td>4</td>
</tr>
<tr>
<td>2</td>
<td>PATHOLOGICAL CLASSIFICATION</td>
<td>5</td>
</tr>
<tr>
<td>3</td>
<td>DIAGNOSIS</td>
<td>5</td>
</tr>
<tr>
<td>3.1</td>
<td>Clinical examination</td>
<td>5</td>
</tr>
<tr>
<td>3.2</td>
<td>Imaging of the testis</td>
<td>5</td>
</tr>
<tr>
<td>3.3</td>
<td>Serum tumour markers</td>
<td>6</td>
</tr>
<tr>
<td>3.4</td>
<td>Inguinal exploration and orchidectomy</td>
<td>6</td>
</tr>
<tr>
<td>3.5</td>
<td>Organ sparing surgery</td>
<td>6</td>
</tr>
<tr>
<td>3.6</td>
<td>Pathological examination of the testis</td>
<td>6</td>
</tr>
<tr>
<td>3.7</td>
<td>Diagnosis and treatment of carcinoma in situ (Tin)</td>
<td>7</td>
</tr>
<tr>
<td>3.8</td>
<td>Screening</td>
<td>7</td>
</tr>
<tr>
<td>4</td>
<td>STAGING</td>
<td>7</td>
</tr>
<tr>
<td>4.1</td>
<td>Diagnostic tools</td>
<td>7</td>
</tr>
<tr>
<td>4.2</td>
<td>Serum tumour markers. Post-orchidectomy half-life kinetics</td>
<td>8</td>
</tr>
<tr>
<td>4.3</td>
<td>Retroperitoneal, mediastinal, supraclavicular lymph nodes and viscera</td>
<td>8</td>
</tr>
<tr>
<td>4.4</td>
<td>Staging and prognostic classifications</td>
<td>9</td>
</tr>
<tr>
<td>4.5</td>
<td>Prognostic risk factors</td>
<td>11</td>
</tr>
<tr>
<td>5</td>
<td>IMPACT ON FERTILITY AND FERTILITY-ASSOCIATED ISSUES</td>
<td>12</td>
</tr>
<tr>
<td>6</td>
<td>GUIDELINES ON DIAGNOSIS AND STAGING OF TESTICULAR CANCER</td>
<td>12</td>
</tr>
<tr>
<td>7</td>
<td>TREATMENT: STAGE I GERM CELL TUMOURS</td>
<td>12</td>
</tr>
<tr>
<td>7.1</td>
<td>Stage I seminoma</td>
<td>12</td>
</tr>
<tr>
<td>7.1.1</td>
<td>Surveillance</td>
<td>12</td>
</tr>
<tr>
<td>7.1.2</td>
<td>Adjuvant chemotherapy</td>
<td>13</td>
</tr>
<tr>
<td>7.1.3</td>
<td>Adjuvant radiotherapy</td>
<td>13</td>
</tr>
<tr>
<td>7.1.4</td>
<td>Retroperitoneal lymph node dissection (RPLND)</td>
<td>13</td>
</tr>
<tr>
<td>7.1.5</td>
<td>Risk-adapted treatment</td>
<td>13</td>
</tr>
<tr>
<td>7.2</td>
<td>Guidelines for the treatment of seminoma stage I</td>
<td>13</td>
</tr>
<tr>
<td>7.3</td>
<td>NSGCT stage I</td>
<td>13</td>
</tr>
<tr>
<td>7.3.1</td>
<td>Surveillance</td>
<td>14</td>
</tr>
<tr>
<td>7.3.2</td>
<td>Primary chemotherapy</td>
<td>14</td>
</tr>
<tr>
<td>7.3.3</td>
<td>Risk-adapted treatment</td>
<td>14</td>
</tr>
<tr>
<td>7.3.4</td>
<td>Retroperitoneal lymph node dissection</td>
<td>14</td>
</tr>
<tr>
<td>7.4</td>
<td>CS1S with (persistently) elevated serum tumour markers</td>
<td>15</td>
</tr>
<tr>
<td>7.5</td>
<td>Guidelines for the treatment of NSGCT stage I</td>
<td>15</td>
</tr>
<tr>
<td>8</td>
<td>TREATMENT: METASTATIC GERM CELL TUMOURS</td>
<td>16</td>
</tr>
<tr>
<td>8.1</td>
<td>Low-volume metastatic disease (stage II A/B)</td>
<td>16</td>
</tr>
<tr>
<td>8.1.1</td>
<td>Stage II A/B seminoma</td>
<td>16</td>
</tr>
<tr>
<td>8.1.2</td>
<td>Stage II A/B non-seminoma</td>
<td>16</td>
</tr>
<tr>
<td>8.2</td>
<td>Advanced metastatic disease</td>
<td>16</td>
</tr>
<tr>
<td>8.2.1</td>
<td>Primary chemotherapy</td>
<td>16</td>
</tr>
<tr>
<td>8.3</td>
<td>Restaging and further treatment</td>
<td>17</td>
</tr>
<tr>
<td>8.3.1</td>
<td>Restaging</td>
<td>17</td>
</tr>
<tr>
<td>8.3.2</td>
<td>Residual tumour resection</td>
<td>17</td>
</tr>
<tr>
<td>8.3.3</td>
<td>Consolidation chemotherapy after secondary surgery</td>
<td>17</td>
</tr>
<tr>
<td>8.4</td>
<td>Systemic salvage treatment for relapse or refractory disease</td>
<td>18</td>
</tr>
<tr>
<td>8.4.1</td>
<td>Seminoma</td>
<td>18</td>
</tr>
<tr>
<td>8.4.2</td>
<td>Non-seminoma</td>
<td>18</td>
</tr>
<tr>
<td>8.4.3</td>
<td>Late relapse (&gt; 2 years after end of first-line treatment)</td>
<td>19</td>
</tr>
<tr>
<td>8.5</td>
<td>Salvage surgery</td>
<td>19</td>
</tr>
<tr>
<td>8.6</td>
<td>Treatment of brain metastases</td>
<td>19</td>
</tr>
</tbody>
</table>

UPDATE MARCH 2008
8.7 Guidelines for the treatment of metastatic germ cell tumours

9 FOLLOW-UP AFTER CURATIVE THERAPY
9.1 General considerations
9.2 Follow-up stage I non-seminoma
  9.2.1 Follow-up during surveillance
  9.2.2 Follow-up after nerve-sparing RPLND
  9.2.3 Follow-up after adjuvant chemotherapy
9.3 Follow-up: stage I seminoma
  9.3.1 Follow-up after radiotherapy
  9.3.2 Follow-up during surveillance
  9.3.3 Follow-up after adjuvant chemotherapy
9.4 Follow-up stage II and advanced (metastatic) disease

10 TESTICULAR STROMAL TUMOURS
10.1 Background
10.2 Methods
10.3 Classification
10.4 Leydig cell tumours
  10.4.1 Epidemiology
  10.4.2 Pathology of Leydig cell tumours
  10.4.3 Diagnosis
  10.4.4 Treatment
  10.4.5 Follow-up
10.5 Sertoli cell tumour
  10.5.1 Epidemiology
  10.5.2 Pathology of Sertoli cell tumours
    10.5.2.1 Classification
  10.5.3 Diagnosis
  10.5.4 Treatment
  10.5.5 Follow-up
10.6 Granulosa cell tumour
10.7 Thecoma/fibroma group of tumours
10.8 Other sex cords/gonadal stromal tumours
10.9 Tumours containing germ cell and sex cord/gonadal stromal (gonadoblastoma)
10.10 Miscellaneous tumours of the testis
  10.10.1 Tumours of ovarian epithelial types
  10.10.2 Tumours of the collecting ducts and rete testis
  10.10.3 Tumours (benign and malignant) of non-specific stroma

11 REFERENCES
11.1 Germ cell tumours
11.2 Non-germ cell tumours

12 ABBREVIATIONS USED IN THE TEXT

UPDATE MARCH 2008
1. BACKGROUND

Testicular cancer represents between 1% and 1.5% of male neoplasms and 5% of urological tumours in general, with 3-6 new cases occurring per 100,000 males/per year in Western society (1,2). An increase in the incidence of testicular cancer was detected during the 1970s and 1980s, particularly in Northern European countries, and there is a clear trend toward an increased testicular cancer incidence in the last 30 years in the majority of the industrialized countries in North America, Europe and Oceania, though surprising differences in incidence rates are seen between neighbouring countries (3). Data from the Surveillance Epidemiology and End Results Program during the years 1973 to 1998 show a continuing increased risk among Caucasian men in USA only for seminoma (4).

Only 1-2% of cases are bilateral at diagnosis. The histological type varies, although there is a clear predominance (90-95%) of germ cell tumours (1). Peak incidence is in the third decade of life for non-seminoma and in the fourth decade for pure seminoma. Familial clustering has been observed, particularly among siblings (5).

Genetic changes have been described in patients with testicular cancer. A specific genetic marker (an isochromosome of the short arm of chromosome 12, i(12p)), has been described in all histological types of germ cell tumours (5). Intratubular germ cell neoplasia (testicular intraepithelial neoplasia, Tin) shows the same chromosomal changes, and alterations in the p53 locus have been found in 66% of cases of testicular Tin (6). A deregulation in the pluripotent programme of fetal germ cells (identified by specific markers like M2A, C-KIT and OCT4/NANOG) is probably responsible for the development of Tin and germ cell neoplasia. There is overlap in the development to seminoma and embryonal carcinoma as shown by genome-wide expression analysis and detection of alpha-fetoprotein (AFP) mRNA in some atypical seminoma (7,8).

Epidemiological risk factors for the development of testicular tumours are: a history of cryptorchidism or undescended testis, Klinefelter’s syndrome, familial history of testicular tumours among first-grade relatives (father/brothers), the presence of a contralateral tumour or Tin and infertility (9-14). Tallness was associated with risk of germ cell cancer although further confirmation is needed (15).

Testicular tumours show excellent cure rates. The main factors contributing to this are: careful staging at the time of diagnosis; adequate early treatment based on chemotherapeutic combinations, with or without radiotherapy and surgery; and very strict follow-up and salvage therapies. In the last decade, a decrease in the mean time delay to diagnosis and to treatment has been observed (16). In the treatment of testicular cancer, the choice of centre where this treatment is going to be administered is of capital importance. Although early stages can be successfully treated in a non-reference centre, the relapse rate is higher (17). In poor prognosis non-seminomatous germ cell tumours, it has been shown that overall survival within a clinical trial depended on the number of patients treated at the participating centre (worse < 5 patients enrolled) (18).

1.1 Methods

The present guidelines represent an implementation of previously published texts; the latest EAU guideline text has been formally published as a review paper in 2005 (19) and as an EAU guideline, which was distributed among EAU members in March 2006. As in 2006, this edition contains a separate chapter on testicular stromal tumours. A multidisciplinary team of urologists, medical oncologists, radiotherapists and a pathologist were involved in producing the present text which is based on a non-structured review of the literature through October 2007 concerning both the germ cell tumour and the non-germ cell part. Also data from meta-analysis studies, Cochrane evidence and the recommendations of the European Germ Cell Cancer Collaborative Group Meeting in Amsterdam November 2006, as well as other available guidelines, have been included (20-26).

Whenever possible, references have been labelled according to the principles of evidence-based medicine (EBM) (27). The nature of the recommendations in the present guidelines is labelled according to the level of evidence (27).
2. PATHOLOGICAL CLASSIFICATION

The recommended pathological classification (modified from the 2004 version of the World Health Organization [WHO]) is shown below (28).

1. Germ cell tumours
   - Intratubular germ cell neoplasia
   - Seminoma (including cases with syncytiotrophoblastic cells)
   - Spermatocytic seminoma (mention if there is sarcomatous component)
   - Embryonal carcinoma
   - Yolk sac tumour
   - Choriocarcinoma
   - Teratoma (mature, immature, with malignant component)
   - Tumours with more than one histological type (specify % of individual components)

2. Sex cord/gonadal stromal tumours
   - Leydig cell tumour
   - Malignant Leydig cell tumour
   - Sertoli cell tumour
     - lipid-rich variant
     - sclerosing
     - large cell calcifying
   - Malignant Sertoli cell tumour
   - Granulosa cell tumour
     - adult type
     - juvenile type
   - Thecoma /fibroma group of tumours
   - Other sex cord/gonadal stromal tumours
     - incompletely differentiated
     - mixed
   - Tumours containing germ cell and sex cord/gonadal stromal (gonadoblastoma)

3. Miscellaneous non-specific stromal tumours
   - Ovarian epithelial tumours
   - Tumours of the collecting ducts and rete testis
   - Tumours (benign and malignant) of non-specific stroma

3. DIAGNOSIS

3.1 Clinical examination

Testicular cancer generally affects young men in the third or fourth decade of life. It normally appears as a painless, unilateral mass in the scrotum or the casual finding of an intrascrotal mass (29). In approximately 20% of cases the first symptom is scrotal pain and up to 27% of patients with testicular cancer may have local pain (1).

Occasionally, trauma to the scrotum may reveal the presence of a testicular mass. Gynaecomastia appears in 7% of cases and is more common in non-seminomatous tumours. Back and flank pain are present in about 11% of cases (16). Reduction in testis size can precede a testicular tumour (30).

In about 10% of cases, a testicular tumour can mimic an orchioepididymitis, with consequent delay of the correct diagnosis (1,2). Ultrasound must be performed in any doubtful case. Physical examination reveals the features of the mass and must always be carried out in conjunction with a general examination in order to find possible (supraclavicular) distant metastases, a palpable abdominal mass or gynaecomastia. A correct diagnosis must be established in all patients with an intrascrotal mass (31).

3.2 Imaging of the testis

Currently, diagnostic ultrasound serves to confirm the presence of a testicular mass and to explore the contralateral testis. Its sensitivity in detecting a testicular tumour is almost 100%, and it has an important role in determining whether a mass is intra- or extratesticular (32). Ultrasound is an inexpensive test, but it is
unnecessary when the presence of a testicular tumour is clinically evident (33). Ultrasound of the testis has to be performed in young men without a palpable testicular mass who have retroperitoneal or visceral masses or elevated serum human chorionic gonadotrophin (hCG) or AFP (34-37). Ultrasound is recommended in the follow-up of the contralateral testis in the follow-up of patients at risk (38).

Magnetic resonance imaging (MRI) offers higher sensitivity and specificity than ultrasound for diagnosing tumours (39-41) and may be able to differentiate seminomatous from non-seminomatous tumours.

MRI of the scrotum offers a sensitivity of 100% and a specificity of 95-100% (42), but its high cost does not justify its use for diagnosis.

3.3 Serum tumour markers at diagnostic

Serum tumour markers are prognostic factors and contribute to diagnosis and staging (43). The following markers should be determined:

- AFP (produced by yolk sac cells)
- hCG (expression of trophoblasts)

Lactate dehydrogenase (LDH) (marker of tissue destruction) is recommended for patients with metastatic disease. Globally, there is an increase in these markers in 51% of cases of testicular cancer (16,29). Alpha-fetoprotein increases in 50-70% of patients with non-seminomatous germ cell tumour (NSGCT) and a rise in hCG is seen in 40-60% of patients with NSGCT. About 90% of non-seminomatous tumours present with a rise in one or two of the markers. Up to 30% of seminomas can present or develop an elevated hCG level during the course of the disease (44,45). Lactate dehydrogenase is a less specific marker, and its concentration is proportional to tumour volume. Its level may be elevated in 80% of patients with advanced testicular cancer (44). It should be noted that negative marker levels do not exclude the diagnosis of a germ cell tumour. Other markers studied include placental alkaline phosphatase (PLAP) which may be of value in monitoring patients with pure seminoma. Cytogenetic and molecular markers are available in specific centres, but at present only contribute to research studies. Measurement of serum AFP, hCG and LDH (in advanced tumours) is mandatory, while PLAP is optional.

3.4 Inguinal exploration and orchidectomy

Every patient with a suspected testicular mass must undergo inguinal exploration with exteriorization of the testis within its tunics, and immediate orchidectomy with division of the spermatic cord at the internal inguinal ring has to be performed if a tumour is found. If the diagnosis is not clear, a testicular biopsy is taken for frozen section histological examination.

In cases of disseminated disease and life-threatening metastases, it is current practice to start with up-front chemotherapy and orchidectomy may be delayed until clinical stabilization has occurred.

3.5 Organ sparing surgery

Although organ sparing surgery is not indicated in the presence of non-tumoural contralateral testis, it can be attempted in special cases with all the necessary precautions.

In synchronous bilateral testicular tumours, metachronous contralateral tumours or in a tumour in a solitary testis with normal pre-operative testosterone levels, organ preserving surgery can be performed when the tumour volume is less than 30% of the testicular volume and surgical rules are respected. In those cases, the rate of associated T1n is high (at least up to 82%) and all patients have to be treated with adjuvant radiotherapy (20 Gy) at some point in time (46).

Infertility will result after radiotherapy and the risk of long-term Leydig cell insufficiency after radiotherapy of a solitary testis is increased (47). Radiation treatment may be delayed in fertile patients who wish to father children. The option has to be carefully discussed with the patient and surgery performed in a centre with experience (48,49).

3.6 Pathological examination of the testis

Mandatory pathological requirements:

- Macroscopic features: side, testis size, maximum tumour size and macroscopic features of epididymis, spermatic cord and tunica vaginalis
- Sampling: 1 cm² section for every cm of maximum tumour diameter, including normal macroscopic parenchyma (if present), albuginea and epididymis, with selection of suspected areas. At least one
proximal and one distal section of spermatic cord plus any suspected area.

- Microscopic features and diagnosis: histological type (specify individual components and estimate amount as percentage) according to WHO 2004 (28):
  - Presence or absence of peri-tumoural venous and/or lymphatic invasion
  - Presence or absence of albuginea, tunica vaginalis, rete testis, epididymis or spermatic cord invasion
  - Presence or absence of intratubular germ cell neoplasia (Tin) in non-tumour parenchyma intratubular germ cell neoplasia

- pT category according to TNM 2002
- Immunohistochemical studies: in seminoma and mixed germ cell tumour, AFP and hCG.

Advisable immunohistochemical markers, in cases of doubt, are:

- In seminoma: cytokeratins (CAM 5.2), PLAP, c-kit
- In intratubular germ cell neoplasia: PLAP, c-kit
- Other advisable markers: chromogranine A (Cg A), Ki-1 (MIB-1).

3.7 Diagnosis and treatment of carcinoma in situ (Tin)

Contralateral biopsy has been advocated to rule out the presence of Tin (50). Although this is routine policy in some countries, the low incidence of Tin and contralateral metachronous testicular tumours (up to 9% and approximately 2.5%, respectively) (58,59), the morbidity of Tin treatment and the fact that most of these metachronous tumours are at a low stage at presentation make it controversial to recommend a systematic contralateral biopsy in all patients (54-56). It is still difficult to reach a consensus whether the existence of contralateral Tin has to be identified in all cases. However, biopsy of the contralateral testis should be offered to high-risk patients for contralateral Tin with a testicular volume less than 12 mL, a history of cryptorchidism and age under 40 years (52,57-59). A double biopsy is preferred to increase sensitivity.

Once Tin is diagnosed, local radiotherapy (20 Gy in single fractions of 2 Gy) is the treatment of choice. Because this may produce infertility, the patient must be carefully counselled before treatment commences (52,60). In addition to infertility, Leydig cell function and testosterone production may be impaired long-term following radiotherapy for Tin (47). Radiation treatment may be delayed in fertile patients who wish to father children.

3.8 Screening

Although there are no surveys proving the advantages of screening programmes, it has been demonstrated that stage and prognosis are directly related to early diagnosis. In the presence of clinical risk factors, self-physical examination by the affected individual is advisable.

4. STAGING

To determine the presence of metastatic or occult disease, the half-life kinetics of serum tumours markers has to be assessed, the nodal pathway has to be screened and the presence of visceral metastases ruled out.

Consequently, it is mandatory to assess:

- Post-orchiectomy half-life kinetics of serum tumour markers
- Status of retroperitoneal and supraclavicular lymph nodes, and the liver
- Presence or absence of mediastinal nodal involvement and lung metastases
- Status of brain and bone, if any suspicious symptoms are present.

4.1 Diagnostic tools

The currently available tests include:

- Serial blood sampling
- Chest X-ray
- Abdominopelvic and thoracic computed tomography (CT) scan
- Abdominal and retroperitoneal ultrasound, magnetic resonance imaging (MRI)
- Positron emission tomography (PET) scan
- Other specific examinations, depending on clinical suspicion.
4.2 Serum tumour markers: post-orchidectomy half-life kinetics
The mean serum half-life of AFP and hCG is 5-7 days and 2-3 days, respectively (44). Tumour markers have to be re-evaluated after orchidectomy to determine half-life kinetics. Marker decline in patients with clinical stage I disease should be assessed until normalization. Post-orchidectomy markers are important to classify the patient according to the IGCCCG (International Germ Cell Cancer Collaborative Group) risk classification. The persistence of elevated serum tumour markers after orchidectomy might indicate the presence of metastatic disease (macro- or microscopically) while normalization of marker levels after orchidectomy does not rule out the presence of tumour metastases. During chemotherapy the markers should decline; persistence has an adverse prognostic value.

4.3 Retroperitoneal, mediastinal, supraclavicular lymph nodes and viscera
Retroperitoneal and mediastinal lymph nodes are best assessed by means of a CT scan. The supraclavicular nodes are best assessed by physical examination.

Abdominopelvic CT scanning offers a sensitivity of 70-80% in determination of the state of retroperitoneal nodes. Its accuracy depends on the size of the nodes; sensitivity and the negative predictive value increase using a 3-mm threshold to define metastatic nodes in the landing zones (61). Those figures decrease slightly in stages I and II (62,63), with a rate of understaging of 25-30% (64). New generations of CT scans do not seem to improve the sensitivity.

Magnetic resonance imaging produces similar results to CT scanning in the detection of retroperitoneal nodal enlargement (65). Again, the main objections to its routine use are high cost and limited access. Nevertheless, MRI can be helpful when abdominopelvic CT or ultrasound are inconclusive (65), when CT scan is contraindicated because of allergy to contrast media, or when the physician or the patient are concerned about radiation dose. Magnetic resonance imaging is an optional test and there are currently no indications for its systematic use in the staging of testicular cancer.

Chest X-ray is the routine thorax examination. An antero-posterior and lateral chest X-ray could be considered the only thoracic examination in seminoma when retroperitoneal and pelvic CT scans are negative (66). A chest CT scan is the most sensitive way to evaluate the thorax and mediastinal nodes. This exploration has to be recommended in patients with NSGCT because up to 10% of cases can present with small subpleural nodes that are not visible radiologically (1). The CT scan has high sensitivity but low specificity (65). A chest CT is mandatory in all patients with NSGCT and in those patients with seminoma and a positive abdominopelvic CT scan (66).

There is not enough evidence to support the use of the fluorodeoxyglucose-positron-emission tomography (FDG-PET) scan in the staging of testis cancer. It is recommended in the follow-up of patients with seminoma at least 4 weeks after chemotherapy with any residual mass in order to decide for watchful waiting or active treatment (67-70).

Table 1: Recommended tests for staging at diagnosis

<table>
<thead>
<tr>
<th>Test</th>
<th>Recommendation grade B</th>
<th>Recommendation grade C</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum tumour markers</td>
<td>Alpha-fetoprotein</td>
<td>hCG</td>
</tr>
<tr>
<td></td>
<td></td>
<td>LDH (for advanced tumours)</td>
</tr>
<tr>
<td>Abdominopelvic CT scan</td>
<td>All patients</td>
<td>Slim adolescent</td>
</tr>
<tr>
<td>Chest X-ray</td>
<td>Seminoma*</td>
<td></td>
</tr>
<tr>
<td>Chest CT scan</td>
<td>NSGCT</td>
<td></td>
</tr>
<tr>
<td>Testis ultrasound</td>
<td>Clinical suspicion and normal scrotum at palpation</td>
<td></td>
</tr>
<tr>
<td>MRI</td>
<td>When abdominal CT is inconclusive</td>
<td>All cases</td>
</tr>
<tr>
<td>PET scan*</td>
<td>Follow-up residual masses in seminoma</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>If clinical suspicion</td>
<td></td>
</tr>
</tbody>
</table>

hCG = human chorionic gonadotrophin; LDH = lactate dehydrogenase; CT = computed tomography; NSGCT = non-seminomatous germ cell tumour; MRI = magnetic resonance imaging; PET = positron emission tomography.
4.4 Staging and prognostic classifications

The staging system recommended in these guidelines is the 2002 TNM of the UICC (International Union Against Cancer) (Table 2) (71). This includes:

- Determination of the anatomical extent of disease
- Assessment of serum tumour markers, including nadir values of hCG, AFP and LDH after orchidectomy (S category)
- Clear definition of regional nodes, and
- Some N category modifications related to the node size.

Table 2: TNM classification for testicular cancer (UICC, 2002, 6th edition)

<table>
<thead>
<tr>
<th>pT</th>
<th>Primary tumour</th>
</tr>
</thead>
<tbody>
<tr>
<td>pTX</td>
<td>Primary tumour cannot be assessed (see 1, T-Primary tumour)</td>
</tr>
<tr>
<td>pT0</td>
<td>No evidence of primary tumour (e.g. histological scar in testis)</td>
</tr>
<tr>
<td>pTis</td>
<td>Intratubular germ cell neoplasia (carcinoma in situ)</td>
</tr>
<tr>
<td>pT1</td>
<td>Tumour limited to testis and epididymis without vascular/lymphatic invasion: tumour may invade tunica albuginea but not tunica vaginalis</td>
</tr>
<tr>
<td>pT2</td>
<td>Tumour limited to testis and epididymis with vascular/lymphatic invasion, or tumour extending through tunica albuginea with involvement of tunica vaginalis</td>
</tr>
<tr>
<td>pT3</td>
<td>Tumour invades spermatic cord with or without vascular/lymphatic invasion</td>
</tr>
<tr>
<td>pT4</td>
<td>Tumour invades scrotum with or without vascular/lymphatic invasion</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>N</th>
<th>Regional Lymph Nodes clinical</th>
</tr>
</thead>
<tbody>
<tr>
<td>NX</td>
<td>Regional lymph nodes cannot be assessed</td>
</tr>
<tr>
<td>N0</td>
<td>No regional lymph node metastasis</td>
</tr>
<tr>
<td>N1</td>
<td>Metastasis with a lymph node mass 2 cm or less in greatest dimension or multiple lymph nodes, none more than 2 cm in greatest dimension</td>
</tr>
<tr>
<td>N2</td>
<td>Metastasis with a lymph node mass more than 2 cm but not more than 5 cm in greatest dimension, or multiple lymph nodes, any one mass more than 2 cm but not more than 5 cm in greatest dimension</td>
</tr>
<tr>
<td>N3</td>
<td>Metastasis with a lymph node mass more than 5 cm in greatest dimension</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>pN</th>
<th>Pathological</th>
</tr>
</thead>
<tbody>
<tr>
<td>pNX</td>
<td>Regional lymph nodes cannot be assessed</td>
</tr>
<tr>
<td>pN0</td>
<td>No regional lymph node metastasis</td>
</tr>
<tr>
<td>pN1</td>
<td>Metastasis with a lymph node mass 2 cm or less in greatest dimension and 5 or fewer positive nodes, none more than 2 cm in greatest dimension</td>
</tr>
<tr>
<td>pN2</td>
<td>Metastasis with a lymph node mass more than 2 cm but not more than 5 cm in greatest dimension; or more than 5 nodes positive, none more than 5 cm; or evidence of extranodal extension of tumour</td>
</tr>
<tr>
<td>pN3</td>
<td>Metastasis with a lymph node mass more than 5 cm in greatest dimension</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>M</th>
<th>Distant Metastasis</th>
</tr>
</thead>
<tbody>
<tr>
<td>MX</td>
<td>Distant metastasis cannot be assessed</td>
</tr>
<tr>
<td>M0</td>
<td>No distant metastasis</td>
</tr>
<tr>
<td>M1</td>
<td>Distant metastasis</td>
</tr>
<tr>
<td>M1a</td>
<td>Non-regional lymph node(s) or lung</td>
</tr>
<tr>
<td>M1b</td>
<td>Other sites</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>S</th>
<th>Serum Tumour Markers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sx</td>
<td>Serum marker studies not available or not performed</td>
</tr>
<tr>
<td>S0</td>
<td>Serum marker study levels within normal limits</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LDH (U/l)</th>
<th>hCG (mIU/ml)</th>
<th>AFP (ng/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>S1</td>
<td>&lt; 1.5 x N and</td>
<td>&lt; 5,000 and</td>
</tr>
<tr>
<td>S2</td>
<td>1.5-10 x N or</td>
<td>5,000-50,000 or</td>
</tr>
<tr>
<td>S3</td>
<td>&gt; 10 x N or</td>
<td>&gt; 50,000 or</td>
</tr>
</tbody>
</table>

N indicates the upper limit of normal for the LDH assay.

LDH = lactate dehydrogenase; hCG = human chorionic gonadotrophin; AFP = alpha-fetoprotein.
Except for PTis and pT4, where radical orchidectomy is not always necessary for classification purposes, the extent of the primary tumour is classified after radical orchidectomy; see pT. In other circumstances, TX is used if no radical orchidectomy has been performed.

According to the 2002 TNM classification, stage I testicular cancer includes the following substages:

<table>
<thead>
<tr>
<th>Stage</th>
<th>pT</th>
<th>N0</th>
<th>M0</th>
<th>S0</th>
</tr>
</thead>
<tbody>
<tr>
<td>IA</td>
<td>pT1</td>
<td>N0</td>
<td>M0</td>
<td>S0</td>
</tr>
<tr>
<td>IB</td>
<td>pT2, pT3 or pT4</td>
<td>N0</td>
<td>M0</td>
<td>S0</td>
</tr>
<tr>
<td>IS</td>
<td>Any pT/TX</td>
<td>N0</td>
<td>M0</td>
<td>S1-3</td>
</tr>
</tbody>
</table>

Stage IA patients have primary tumours limited to the testis and epididymis, with no evidence of microscopic vascular or lymphatic invasion by tumour cells on microscopy, no sign of metastases on clinical examination or imaging, and post-orchidectomy serum tumour marker levels within normal limits. Marker decline in patients with clinical stage I disease should be assessed until normalization. Stage IB patients have a more locally invasive primary tumour, but no sign of metastatic disease. Stage IS patients have persistently elevated (and usually increasing) serum tumour marker levels after orchidectomy, which is evidence of subclinical metastatic disease (or possibly a second germ cell tumour in the remaining testis). If serum tumour marker levels are declining according to the expected half-time decay after orchidectomy, the patient is usually followed up until normalization.

In large, population-based patient series, 75-80% of seminoma patients and about 55% of patients with non-seminomatous germ cell testicular cancer (NSGCT) have stage I disease at diagnosis (72,73). True stage IS (persistently elevated or increasing serum marker levels after orchidectomy) is found in about 5% of non-seminoma patients. If a staging RPLND was to be performed in stage IS patients, nearly all patients would be found have pathological stage II disease (pN+) (1,2,5,72).

In 1997, the IGCCCG defined a prognostic factor-based staging system for metastatic testis tumour based on identification of some clinical independent adverse factors. This staging system has been incorporated into the TNM Classification and uses histology, location of the primary tumour, location of metastases and pre-chemotherapy markers levels in serum as prognostic factors to categorize patients into ‘good’, ‘intermediate’ or ‘poor’ prognosis (Table 3) (74).

Table 3: Prognostic-based staging system for metastatic germ cell cancer
(International Germ Cell Cancer Collaborative Group)

<table>
<thead>
<tr>
<th>Good-prognosis group</th>
<th>Non-seminoma (56% of cases)</th>
<th>All of the following criteria:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>5-year PFS 89%</td>
<td>Testis/retroperitoneal primary</td>
</tr>
<tr>
<td></td>
<td>5-year survival 92%</td>
<td>No non-pulmonary visceral metastases</td>
</tr>
<tr>
<td></td>
<td></td>
<td>AFP &lt; 1,000 ng/mL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>hCG &lt; 5,000 IU/L (1,000 ng/mL)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>LDH &lt; 1.5 x ULN</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Seminoma (90% of cases)</th>
<th>5-year PFS 82%</th>
<th>5-year survival 86%</th>
</tr>
</thead>
<tbody>
<tr>
<td>All of the following criteria:</td>
<td>Any primary site</td>
<td>No non-pulmonary visceral metastases</td>
</tr>
<tr>
<td></td>
<td>Normal AFP</td>
<td>Any hCG</td>
</tr>
<tr>
<td></td>
<td>Any LDH</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Intermediate prognosis group</th>
<th>Non-seminoma (28% of cases)</th>
<th>All of the following criteria:</th>
</tr>
</thead>
<tbody>
<tr>
<td>5 years PFS 75%</td>
<td>Testis/retroperitoneal primary</td>
<td></td>
</tr>
<tr>
<td>5-year survival 80%</td>
<td>No non-pulmonary visceral metastases</td>
<td></td>
</tr>
<tr>
<td></td>
<td>AFP &gt; 1,000 and &lt; 10,000 ng/mL or</td>
<td></td>
</tr>
<tr>
<td></td>
<td>hCG &gt; 5,000 and &lt; 50,000 IU/L or</td>
<td></td>
</tr>
<tr>
<td></td>
<td>LDH &gt; 1.5 and &lt; 10 x ULN</td>
<td></td>
</tr>
</tbody>
</table>

UPDATE MARCH 2008
Seminoma (10% of cases)
5-year PFS 67%
5-year survival 72%

Any of the following criteria:
• Any primary site
• Non-pulmonary visceral metastases
• Normal AFP
• Any hCG
• Any LDH

Poor prognosis group
Non-seminoma (16% of cases)
5-year PFS 41%
5-year survival 48%

Any of the following criteria:
• Mediastinal primary
• Non-pulmonary visceral metastases
• AFP > 10,000 ng/mL or
• hCG > 50,000 IU/L (10,000 ng/mL) or
• LDH > 10 x ULN

Seminoma
No patients classified as poor prognosis

PFS = progression-free survival; AFP = alpha-fetoprotein; hCG = human chorionic gonadotrophin; LDH = lactate dehydrogenase.

4.5 Prognostic risk factors

For seminoma stage I, tumour size (> 4 cm) and invasion of the rete testis have been identified as the most important predictors for relapse in multivariate analysis (20).

For non-seminoma stage I, vascular invasion of the primary tumour in blood or lymphatic vessels is the most important predictor of occult metastatic disease. The proliferation rate, as well as the percentage of embryonal carcinoma, are additional predictors that improve upon the positive and negative predictive value of vascular invasion (75,76).

The significant prognostic pathological risk factors for stage I and clinical risk factors for metastatic disease are listed in Table 4.

Table 4: Prognostic factors for occult metastatic disease in testicular cancer

Pathological (for stage I)
• Histopathological type
• For seminoma
  Tumour size (> 4 cm)
  Invasion of the rete testis
• For non-seminoma
  Vascular/lymphatic in or peri-tumoural invasion
  Proliferation rate > 70%
  Percentage of embryonal carcinoma > 50%

Clinical (for metastatic disease)
• Primary location
• Elevation of tumour marker levels
• Presence of non-pulmonary visceral metastasis
5. **IMPACT ON FERTILITY AND FERTILITY-ASSOCIATED ISSUES**

Sperm abnormalities are frequently found in patients with testis tumours. Furthermore, chemotherapy and radiation treatment can also impair fertility. In patients in the reproductive age, pre-treatment fertility assessment (testosterone, luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels) should be performed and semen analysis and cryopreservation should be offered. If cryopreservation is desired, it should be performed before or after orchidectomy, but in any case prior to chemotherapy treatment (47,77-83). In case of bilateral orchidectomy or low testosterone levels after treatment of TIN, life-long testosterone supplementation is necessary (84). For more detailed information, the reader is referred to the EAU Male Infertility Guidelines.

6. **GUIDELINES ON DIAGNOSIS AND STAGING OF TESTICULAR CANCER**

1. Testicular ultrasound is mandatory. (Grade of recommendation: B).
2. Orchidectomy and pathological examination of the testis is necessary to confirm the diagnosis and to define the local extension (pT category) (Grade B recommendation). In a life-threatening situation due to extensive metastasis chemotherapy has to be started before orchidectomy.
3. Serum determination of tumour markers (AFP, hCG, and LDH in metastatic disease) must be performed before and after orchidectomy for staging and prognostic reasons (Grade of recommendation: B).
4. Retroperitoneal, mediastinal and supraclavicular nodes and visceral state have to be assessed in testicular cancer. In seminoma, a chest CT scan is not necessary if abdominal nodes are negative (Grade of recommendation: B).

7. **TREATMENT: STAGE I GERM CELL TUMOURS**

7.1 **Stage I seminoma**

After modern staging procedures, about 15-20% of stage I seminoma patients have subclinical metastatic disease, usually in the retroperitoneum, and will relapse after orchidectomy alone (85).

7.1.1 **Surveillance**

Several prospective non-randomized studies of surveillance have been conducted during the last decade, the largest study coming from Canada with > 1,500 patients (86). Previous meta-analysis from four studies showed an actuarial 5 years’ relapse-free rate of 82.3%. The Princess Margaret Hospital series (n = 1559) showed an overall relapse rate in unselected patients of 16.8%. The actuarial relapse rate is of the order of 15-20% at 5 years, and most of the relapses are first detected in infra-diaphragmatic lymph nodes (85,87-89).

Chemotherapy with dosing according to IGCCCG classification is a possible treatment for seminoma relapse under surveillance. Seventy percent of patients with relapse, however, are suitable for treatment with radiotherapy again because of small volume disease at the time of recurrence. Only about 20% of these patients relapse again after salvage radiotherapy and then need salvage chemotherapy. The overall cancer-specific survival rate reported with surveillance performed by experienced centres is 97-100% for seminoma stage I (88,89). The main drawback of surveillance is the need for more intensive follow-up, especially with repeated imaging examinations of the retroperitoneal lymph nodes, for at least 5 years after orchidectomy. This compares with the very low risk of subdiaphragmatic relapse after adjuvant radiotherapy.

About 20% of the relapses seen after surveillance occur more than 4 years after orchidectomy (88). Cost analyses of surveillance compared with radiotherapy indicate that it is more expensive (90), but estimates vary depending basically on the follow-up schedules (91,92).
7.1.2 Adjuvant chemotherapy

A joint trial between the Medical Research Council (MRC) and European Organization for Research and Treatment of Cancer (EORTC) (MRC TE 19 trial), which compared one cycle of carboplatin (AUC [area under curve] 7) to adjuvant radiotherapy, did not show a significant difference concerning recurrence rate, time to recurrence and survival after a median follow-up of 4 years (93). Therefore, adjuvant carboplatin therapy is an alternative to radiotherapy or surveillance in stage I seminoma (88,89,93). Two courses of adjuvant carboplatin seem to further reduce the relapse rate to the order of 1-3% (96,97) but further experience and long-term observations are needed.

7.1.3 Adjuvant radiotherapy

Seminoma cells are extremely radiosensitive. Adjuvant radiotherapy to a para-aortic (PA) field or to a hockey stick field (para-aortic and ipsilateral iliacal nodes), with moderate doses (total 20-24 Gy), will reduce the relapse rate to only 1-3% (98-101). After modern radiotherapy, nearly all relapses will first occur outside the irradiated field (supradiaphragmatic lymph nodes or in the lungs) (98,101). Based upon the results of a large randomized MRC trial, Fossa et al. (98,99) recommended radiotherapy to a para-aortic field as standard treatment for patients with testicular seminoma stage I, T1-T3 and with undisturbed lymphatic drainage. Acute toxicity was reduced and the sperm count within the first 18 months was significantly higher after para-aortic irradiation than after irradiation of the traditional dog-leg field. On the other hand, the relapse rate in the iliac lymph nodes was about 2% (all of them on the right side) after para-aortic and 0% after dog-leg irradiation. Another possible site of failure is in the left renal hilum. Para-aortic irradiation should be tailored according to the site of the primary tumour. Adjuvant irradiation of supradiaphragmatic lymph nodes is not indicated in seminoma stage I.

Concerning the dose of irradiation, the MRC recently has finished a large randomized trial of 20 Gy versus 30 Gy para-aortic radiation in stage I seminoma that showed equivalence for both doses regarding recurrence rates (99). The rate of severe radiation-induced long-term toxicity is less than 2%. Moderate chronic gastrointestinal (GI) side-effects are seen in about 5% of patients and moderate acute GI toxicity in about 60% (98). The main concern surrounding adjuvant radiotherapy is the potentially increased risk of radiation-induced secondary non-gem-cell malignancies (102-104). A scrotal shield can be of benefit during adjuvant radiotherapy in order to prevent scattered radiation toxicity in the contralateral testis (105). At this point in time, it is difficult to evaluate the long-term risks after adjuvant radiotherapy for stage I seminoma because former treatment procedures included larger fields, higher doses of radiotherapy and/or the use of alkylating chemotherapy.

7.1.4 Retroperitoneal lymph node dissection (RPLND)

In a prospective, non-randomized study comparing radiotherapy and RPLND in stage I seminoma, there was a trend towards a higher incidence of retroperitoneal relapses (9.5%) after RPLND as primary treatment. Therefore this policy should not be recommended in stage I seminoma (94).

7.1.5 Risk-adapted treatment

Using tumour size > 4 cm and rete testis invasion, patients with seminoma stage I may be subdivided into a low-and high-risk group of occult metastatic disease. Patients with and without both risk factors have a risk of occult disease of 32% and 12%, respectively. These risk factors were introduced by a meta-analysis of retrospective trials (20). A prospective trial based on these risk factors (no risk factors: surveillance; both risk factors: two courses carboplatin AUC 7) showed the feasibility of a risk-adapted approach. Early data with limited follow-up indicate that patients without either risk factor have a 6.0% risk of relapse at 5 years. Patients at high risk treated with carboplatin experienced a 3.3% relapse rate (95).

7.2 GUIDELINES FOR THE TREATMENT OF SEMINOMA STAGE I

1. Surveillance (if available facilities and patient compliance) (Grade of recommendation: B).
2. Carboplatin based chemotherapy (one course at AUC 7) can be recommended as an alternative to radiotherapy and surveillance (Grade of recommendation: A).
3. Adjuvant radiotherapy to a para-aortic or a hockey stick field, to a total dose of 20 Gy (Grade of recommendation: A).

7.3 NSGCT stage I

Up to 30% of NSGCT patients with clinical stage I (CS1) disease have subclinical metastases and will relapse if surveillance alone is applied after orchidectomy.
7.3.1 Surveillance

Improvements in clinical staging and follow-up methods, and the availability of effective salvage treatment with cisplatin-based chemotherapy and post-chemotherapy surgery, have led to studies of only close surveillance after orchidectomy in CS1 NSGCT patients. The largest reports of the surveillance strategy indicate a cumulative relapse rate of about 30%, with 80% of relapses occurring during the first 12 months of follow-up, 12% during the second year and 6% during the third year, decreasing to 1% during the fourth and fifth years, and occasionally even later (106-109). About 35% of relapsing patients have normal levels of serum tumour markers at relapse. About 60% of relapses are in the retroperitoneum. Despite very close follow-up, 11% of relapsing patients presented with large-volume recurrent disease.

The somewhat lower relapse rates reported from surveillance studies compared with some series of patients staged by RPLND (110) can be explained by the fact that some patients (presumably at risk) are excluded once surveillance is advised. Based on the overall cancer-specific survival data, surveillance within an experienced surveillance programme may be offered to patients with non-risk stratified clinical stage I non-seminoma as long as they are compliant and informed about the expected recurrence rate as well as the salvage treatment (111).

7.3.2 Primary chemotherapy

Several studies involving two courses of chemotherapy with bleomycin, etoposide and cisplatin (PEB) as primary treatment for high-risk patients (having about 50% risk of relapse) have been reported (112-117). In these series, involving more than 200 patients, some with a median follow-up of nearly 8 years (112), a relapse rate of only 2.7% was reported, with very little long-term toxicity. Two cycles of cisplatinum-based adjuvant chemotherapy do not seem to adversely affect fertility or sexual activity (118). It is important to be aware of the slow-growing retroperitoneal teratomas after primary chemotherapy and of the risk of late chemoresistant cancer relapse (119). The need for repeated and long-term follow-up with imaging of the retroperitoneum after primary chemotherapy is not yet clear. The results of cost analyses comparing surveillance, RPLND and primary chemotherapy show different results among the reported studies, possibly because of differences in intensity and costs related to follow-up procedures (120). With a low frequency of follow-up CTs for instance, as has been proven effective for the surveillance strategy in non-seminoma CS I), the costs of follow-up can considerably be reduced (121).

7.3.3 Risk-adapted treatment

Risk-adapted treatment is currently based on the risk factor vascular invasion. Stratifying patients with CS1 NSGCT according to their presumed risk of relapse is a rational option, as several studies have reported similar survival rates and a final cure rate close to 100% with all available treatment options using the risk-stratifying approach (112-117,122-124). Therefore, risk-adapted treatment is an equally effective alternative treatment of choice in CS1 NSGCT. Patients with vascular invasion are recommended to undergo adjuvant chemotherapy with two cycles of PEB and patients without vascular invasion are recommended to undergo surveillance. Only if patients or doctors are not willing to accept the accordingly risk-adapted treatment or if there are conditions against the risk-adapted treatment option, the remaining treatments should be considered. Thus, the treatment decision should be based on a thorough discussion with the patients, taking into account the described advantages and disadvantages, as well as the individual situation of the patient and/or the treatment centre.

7.3.4 Retroperitoneal lymph node dissection

If RPLND is performed, about 30% of patients are found to have retroperitoneal lymph node metastases, which corresponds to pathological stage II (PS2) disease (94,125,126). If no retroperitoneal metastases are found at RPLND (PS1), approximately 10% of the PS1 patients relapse at distant sites (76,110,127-129).

The main predictor of relapse in CS1 NSGCT managed by surveillance, and both for having PS2 disease and for relapse in PS1 after RPLND, is histopathological evidence of vascular invasion by tumour cells in, or near, the primary tumour in the testis (76,106,110,129,130). The presence of vascular invasion seems to be a very robust parameter, and is clinically usable even without centralized review by an expert panel (122,129). Vascular invasion was the most predictive of stage in a multifactorial analysis. The absence of vascular invasion has a negative predictive value of 77%, thus allowing for surveillance in low-risk compliant patients (76).

Patients without vascular invasion constitute about 50-70% of the CS1 population, and these patients have only a 15-20% risk of relapse on surveillance, compared with a 50% relapse rate in patients with vascular invasion. The risk of relapse for PS1 patients is less than 10% for those without vascular invasion and about 30% for those with vascular invasion (122,129,131,132).

If CS1 patients with PS2 are only followed up after RPLND, about 30% relapse, mainly at sites outside the
abdomen and pelvis. The risk of relapse depends upon the amount of retroperitoneal disease resected (133-135). If two (or more) courses of cisplatin-based chemotherapy are given adjuvant to RPLND in PS2 cases, the relapse rate is reduced to less than 2%, including teratoma relapse (110,130,136). The risk of retroperitoneal relapse after a properly performed nerve-sparing RPLND is very low (less than 2%), as is the risk of ejaculatory disturbance or other significant side effects (130,133,134). The follow-up after RPLND is much simpler and less costly than that carried out during post-orchidectomy surveillance due to the reduced need for abdominal CT scans (130). A laparoscopic RPLND may become a good alternative to an open staging RPLND, but currently cannot be recommended as a standard diagnostic tool (137-140). In a randomized comparison of RPLND to one course of PEB chemotherapy, adjuvant chemotherapy significantly increased the 2-year recurrence free survival to 99.41% (confidence interval (CI) [95.87%, 99.92%]) as opposed to surgery with 92.37%, (CI [87.21%, 95.50%]). The difference was 7.04%, CI [2.52%, 11.56%]. The hazard ratio to experience a tumour recurrence with surgery as opposed to chemotherapy was 7.937, CI [1.808, 34.48]. Therefore, one course of adjuvant PEB is superior to RPLND with regard to recurrence rates in patients unstratified for risk factors (141).

7.4 CS1S with (persistently) elevated serum tumour markers
Serum tumour markers should be followed closely until levels are falling into the reference values according to the expected half-time values for AFP and hCG. If the marker level increases after orchidectomy, the patient has residual disease. If RPLND is performed, up to 87% of these patients have pathologically documented nodes in the retroperitoneum (142). An ultrasound examination of the contralateral testicle must be performed, if this has not been done initially.

The treatment of true CS1S patients is still controversial. They may be treated with three courses of primary PEB chemotherapy and with follow-up as for CS1B (high risk; see below) patients after primary chemotherapy (143), or by RPLND (120). The presence of vascular invasion may strengthen the indication for primary chemotherapy as most CS1S with vascular invasion will need chemotherapy sooner or later anyway.

7.5 GUIDELINES FOR THE TREATMENT OF NSGCT STAGE I

CS 1
Risk-adapted treatments based on vascular invasion or surveillance are recommended treatment options (Grade of recommendation: B)

CS1A (pT1, no vascular invasion): low risk
1. If the patient is willing and able to comply with a surveillance policy and long-term (at least 5 years) close follow-up should be recommended (Grade of recommendation: B).
2. Adjuvant chemotherapy or nerve-sparing RPLND in low-risk patients remain options for those not willing to undergo surveillance. If RPLND reveals PN+ (nodal involvement) disease, chemotherapy with two courses of PEB should be considered (Grade of recommendation: A).

CS1B (pT2-pT4): high risk
1. Primary chemotherapy with two courses of PEB should be recommended (Grade of recommendation: B).

Surveillance or nerve-sparing RPLND in high-risk patients remain options for those not willing to undergo adjuvant chemotherapy. If pathological stage II is revealed at RPLND, further chemotherapy should be considered (Grade of recommendation: A).
8. TREATMENT: METASTATIC GERM CELL TUMOURS

Treatment of metastatic germ cell tumours depends on:
• Histology of the primary tumour
• Prognostic groups as defined by the IGCCCG based on 5,202 non-seminoma and 660 seminoma cases (Table 3) (144).

8.1 Low-volume metastatic disease (Stage II A/B)

8.1.1 Stage II A/B seminoma

The standard treatment of stage II A/B seminoma has been radiotherapy so far. The radiation dose delivered in stage IIA and IIB is 30 Gy and 36 Gy, respectively. The standard radiation field compared to stage I will be extended from the para-aortic region to the ipsilateral iliac field (‘hockey-stick’). In stage IIB, the lateral borders should include the metastatic lymph nodes with a safety margin of 1.0-1.5 cm. This technique yields a relapse-free survival after 6 years for stage IIA and IIB of 95% and 89%, respectively. Overall survival is almost 100% (60,88).

In stage IIB chemotherapy with 3 cycles PEB or alternatively 4 cycles EP (‘good prognosis’) is an alternative for patients not willing to undergo radiotherapy. Single-agent carboplatin is not an alternative to standard PEB chemotherapy (145).

8.1.2 Stage II A/B non-seminoma

There is a general consensus that treatment should start with initial chemotherapy in all advanced cases of NSGCT except for stage II NSGCT disease without elevated tumour markers, which alternatively can be treated with primary RPLND or surveillance (146,147). These rare cases of Stage IIA/B without marker elevation may represent metastatic differentiated teratoma or pure embryonal carcinoma. Stage II A/B non-seminoma with elevated markers will be treated according to IGCCCG ‘good or intermediate prognosis’ NSGCT (3 or 4 cycles PEB, followed by residual tumour resection) (148,149). About 30% of patients will not achieve a complete remission after chemotherapy and will need a residual tumour resection.

Patients not willing to undergo primary chemotherapy have the option of primary nerve-sparing RPLND with adjuvant chemotherapy (2 cycles PEB) in case of metastatic disease (pII A/B). Primary chemotherapy and primary RPLND are comparable options in terms of outcome but side effects and toxicity are different, allowing for involvement of the patient in selecting the treatment of choice (150). The cure rate with either approach will be close to 98% (136,151-156).

8.2 Advanced metastatic disease

8.2.1 Primary chemotherapy

The primary treatment of choice for advanced disease is three or four cycles of PEB combination chemotherapy (Table 5), depending on IGCCCG risk classification (see Table 3). This regimen has proven superiority to cisplatin, vinblastine and bleomycin (PVB) in patients with advanced disease (157-159). Data support that a 3-day regimen of administering combination chemotherapy is equally effective as a 5-day regimen but associated with increased toxicity (160).

Table 5: PEB regimen (every 3 weeks)

<table>
<thead>
<tr>
<th>Drug</th>
<th>PEB</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cisplatin</td>
<td>20 mg/m², days 1-5*</td>
</tr>
<tr>
<td>Etoposide</td>
<td>100 mg/m², days 1-5</td>
</tr>
<tr>
<td>Bleomycin</td>
<td>30 mg, days 1,8,15</td>
</tr>
</tbody>
</table>

PEB = cisplatin, etoposide and bleomycin.

For patients with a ‘good prognosis’, according to the IGCCCG Classification (144), standard treatment consists of three cycles of PEB or, in the case of contraindication against bleomycin, of four cycles of EP (144,159-163). Therapy should be given without reduction of the doses in 22-day intervals; delaying the chemotherapy cycle is justified only in case of fever with granulocytopenia < 1,000/mm³ or thrombocytopenia < 100,000/UI. There is no indication for prophylactic application of haematopoetic growth factors as, for example, granulocyte colony-stimulating factor (G-CSF). However, if infectious complications have occurred under chemotherapy, prophylactic administration of G-CSF is recommended for the following cycles (161,164).
With the ‘intermediate prognosis’ group in the IGCCCG, a group of patients has been defined who reach a 5-year survival rate of about 80%. The available data support 4 cycles of PEB as standard treatment (144,165). Due to the generally less favourable prognosis of this patient group, in comparison to patients with a ‘good prognosis’, they may be treated in prospective trials such as, for example, the EORTC GU Group trial with PEB vs PEB+Paclitaxel (165).

For patients with a ‘poor prognosis’, standard treatment consists of 4 cycles of PEB. Four cycles of PEI (cisplatin, etoposide, ifosfamide) have the same effect, but are more toxic (166,167). The 5-year progression-free survival is between 45% and 50%. A randomized study has shown no advantage of high-dose chemotherapy for the overall group of ‘poor prognosis’ patients. However, patients with a slow marker decline may represent a prognostically inferior subgroup (168). Since a matched-pair analysis resulted in a better survival rate (169,170), poor prognosis patients should still be treated in ongoing prospective randomized trials, investigating the value of high-dose chemotherapy. Patients meeting ‘poor-prognosis’ criteria should therefore be transferred to a reference centre. Any general recommendations for treatment modifications for patients with a poor general condition (Karnofsky < 50%), extended liver infiltration (> 50%) and extended pulmonary infiltration do not exist.

8.3 Restaging and further treatment

8.3.1 Restaging

After termination of two courses of chemotherapy, re-evaluation is performed by imaging investigations and determination of tumour markers. At marker decline and stable or regressive tumour manifestation, chemotherapy will be completed (3 or 4 cycles, depending on the initial stage) (144,171,172). In the case of marker decline, but growing metastases, resection of the tumour is obligatory after termination of induction therapy, unless in an emergency according to local tumour growth (173).

Only with documented marker growth after 2 courses of chemotherapy, an early crossover of therapy is indicated. These patients are usually candidates for new drugs trials (169,174). Patients with a low-level marker plateau post treatment will be observed, whether or not complete normalization occurs. Salvage chemotherapy is indicated for documented marker rise only (175,176).

8.3.2 Residual tumour resection

A residual mass of seminoma will not be resected, irrespective of the size, but controlled by imaging investigations and tumour markers (177-183).

FDG-PET has a high prognostic value in patients with residual masses after treatment of seminoma. In patients with residuals of > 3 cm, FDG-PET should be performed in order to gain more information on the viability of these residuals. In patients with residuals of < 3 cm, the use of FDG-PET is optional (184). On progression, salvage chemotherapy will be given, if necessary including surgery and radiotherapy (185-189).

In the case of non-seminoma and complete remission after chemotherapy (no tumour visible), residual tumour resection is not indicated (190-195). In the case of any visible residual mass and marker normalization, surgical resection is indicated. In patients with lesions < 1 cm, there still is an increased risk of residual cancer or teratoma (196). In persistent retroperitoneal disease, all areas of primary metastatic sites have to be completely resected within 4-6 weeks after completion of chemotherapy. If technically feasible, a nerve-sparing procedure should be performed (190,197-204).

Overall, following PEB induction chemotherapy, only 10% of residual masses contain viable cancer, 50% contain mature teratoma and 40% contain necrotic-fibrotic tissue. As yet no imaging investigation, including PET or a prognosis model, are able to predict histological differentiation of the non-seminomatous residual tumour. Thus, residual tumour resection is mandatory (191-193,205-213).

The extent of surgery should be based on the risk of relapse of an individual patient and quality of life issues (198). If possible, all the masses have to be resected because a complete resection, in the setting of viable malignant cells, is more critical than recourse to post-operative chemotherapy (214). Histology in different organ sites may diverge (206).

8.3.3 Consolidation chemotherapy after secondary surgery

After resection of necrosis or mature teratoma, no further treatment is required. In the case of incomplete resection of vital carcinoma or immature teratoma, two adjuvant cycles of conventionally dosed cisplatinum-based chemotherapy may be given in certain subgroups (e.g. ‘poor prognosis’ patients) (214) (cave: cumulative doses of bleomycin). After complete resection of vital tumour < 10% of the total volume, adjutant
chemotherapy is not beneficial for preventing further relapse. The prognosis will definitely deteriorate if vital carcinoma is found in resection specimens after second- and third-line chemotherapy. In this latter situation, post-operative chemotherapy is not indicated and is unable to improve the prognosis (202,207).

8.4 Systemic salvage treatment for relapse or refractory disease

8.4.1 Seminoma

Cisplatin-based combination salvage chemotherapy will result in long-term remissions for about 50% of patients who relapse after first-line chemotherapy (215). The regimens of choice are 4 cycles of PEI/VIP (cisplatin, etoposide, ifosfamide), 4 cycles of TIP (paclitaxel, ifosfamide, cisplatin) or 4 cycles of VeIP (vinblastin, ifosfamide, cisplatin). At present, it is impossible to determine whether conventionally dosed cisplatin-based combination chemotherapy is sufficient as first-salvage treatment or whether early intensification of first-salvage treatment with high-dose chemotherapy should be attempted (216). Therefore, treatment of these rare patients within clinical trials and at experienced centres is of the utmost importance.

8.4.2 Non-seminoma

Standard salvage treatment after first-line chemotherapy consists of either 4 cycles of PEI/VIP, 4 courses of TIP or 4 cycles of VeIP, respectively (Table 6). Conventionally dosed salvage chemotherapy may achieve long-term remissions in 15-40% of patients, depending on individual risk factors (176,217). Prognostic indicators of response to salvage therapy are: (176,217-219)

- Location and histology of the primary tumour
- Response to first-line treatment
- Duration of remissions
- Level of AFP and hCG at relapse.

Salvage therapy with VeIP is probably not superior to other conventionally dosed cisplatin-based combination regimens (216-218). The use of conventionally dosed combination regimens with more than three agents will increase toxicity without improving treatment outcome (220).

Depending on the presence of adverse prognostic factors, the results of salvage therapy after first-line cisplatin based treatment are unsatisfactory (176,221). Although some phase II trials indicate a 10% improvement in survival with early intensification of first-salvage treatment using high-dose chemotherapy, others fail to demonstrate such improvement (222-226).

No advantage from high-dose chemotherapy was observed according to the results of the randomized IT 94 trial in good-risk patients (227). Therefore, patients with good prognostic features should be offered conventional-dose salvage treatment. Several phase II trials, as well as one retrospective matched-pair analysis, have shown an improvement in survival in poor-prognosis patients with early intensification of first-salvage treatment using high-dose chemotherapy (218,228-230) (EBM IIB).

Recently, taxol and gemcitabine have proved to be active in the treatment of refractory germ cell tumours; both drugs are synergistic with cisplatin (231-233). However, all of these patients should be entered into ongoing multicentre studies to define the optimal approach to salvage treatment and should be referred to centres experienced in caring for relapse and/or refractory patients (216).

Table 6: Standard PEI/VIP, TIP and VeIP chemotherapy

<table>
<thead>
<tr>
<th>PEI/VIP</th>
<th>Dosage</th>
<th>Duration of cycles</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cisplatin</td>
<td>20 mg/m², days 1-5</td>
<td>21 days</td>
</tr>
<tr>
<td>Etoposide</td>
<td>75-100 mg/m², days 1-5</td>
<td></td>
</tr>
<tr>
<td>Ifosfamide</td>
<td>1.2 g/m², days 1-5</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TIP</th>
<th>Dosage</th>
<th>Duration of cycles</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paclitaxel</td>
<td>250 mg/m²</td>
<td>24 hour continuous infusion day 1</td>
</tr>
<tr>
<td>Ifosfamide</td>
<td>1.5 g/ m²</td>
<td>days 2-5</td>
</tr>
<tr>
<td>Cisplatin</td>
<td>25 mg/m²</td>
<td>days 2-5</td>
</tr>
<tr>
<td>VeIP</td>
<td>Dosage</td>
<td>Duration of cycles</td>
</tr>
<tr>
<td>--------------</td>
<td>-----------------------------</td>
<td>--------------------</td>
</tr>
<tr>
<td>Vinblastin</td>
<td>0.11 mg/kg, days 1 + 2</td>
<td>21 days</td>
</tr>
<tr>
<td>Ifosfamide</td>
<td>1.2 g/m², days 1-5</td>
<td></td>
</tr>
<tr>
<td>Cisplatin</td>
<td>20 mg/m², days 1-5</td>
<td></td>
</tr>
</tbody>
</table>

PEI/VIP = cisplatin, eposide, ifosfamide; TIP = paclitaxel, ifosfamide, cisplatin; VeIP = vinblastin, ifosfamide, cisplatin.

8.4.3 Late relapse (> 2 years after end of first-line treatment)
Late relapse is defined as any patient relapsing more than 2 years following chemotherapy for metastatic disease. If technically feasible, all patients with late relapse should undergo immediate radical surgery of all lesions, irrespective of the level of their tumour markers to completely resect all undifferentiated germ-cell tumour, mature teratoma or secondary non-germ cell cancer (119,234). If the lesions are not completely resectable, biopsies should be obtained for histological assessment and salvage chemotherapy should be initiated according to the histological results. If the patient responds to salvage chemotherapy, secondary surgery should be conducted whenever possible. In the case of unresectable, but localised, refractory disease, radiotherapy can be considered. To avoid excess mortality, late relapses should only be treated at centres experienced in managing such patients (235).

8.5 Salvage surgery
Residual tumours after salvage chemotherapy should be resected within 4-6 weeks after marker normalization or when a marker plateau is reached. In the case of marker progression after salvage treatment and a lack of other chemotherapeutic options, resection of residual tumours (‘desperation surgery’) should be considered if complete resection of all tumour seems feasible (about 25% long-term survival may be achieved) (176,200,208,211,236-245).

8.6 Treatment of brain metastases
Brain metastases occur in the frame of a systemic relapse and rarely as an isolated relapse. The long-term survival of patients presenting with brain metastasis at initial diagnosis is poor (30-40%), but even poorer is the development of a brain metastases as a recurrent disease (5 years’ survival is 2-5%) (246,247). Chemotherapy is the initial treatment in this case and some data support the use of consolidation radiotherapy, even in the case of a total response after chemotherapy (248). Surgery can be considered in the case of a persistent solitary metastasis, depending on the systemic state, the histology of the primary tumour and the location of the metastasis.

8.7 GUIDELINES FOR THE TREATMENT OF METASTATIC GERM CELL TUMOURS
1. Low volume NSGCT stage IIA/B with elevated markers should be treated like ‘good or intermediate prognosis’ advanced NSGCT with 3 or 4 cycles of PEB. Stage II A/B without marker elevation can be treated either by RPLND or close surveillance.
2. In metastatic NSGCT (> stage IIC) with a good prognosis, three courses of PEB is the primary treatment of choice (Grade of recommendation: A).
3. In metastatic NSGCT with an intermediate or poor prognosis, the primary treatment of choice is four courses of standard PEB (Grade of recommendation: A).
4. Surgical resection of residual masses after chemotherapy in NSGCT is indicated in the case of visible residual masses and when serum levels of tumour markers are normal or normalizing (Grade of recommendation: B).
5. CSII A/B can initially be treated with radiotherapy. When necessary, chemotherapy can be used as a salvage treatment with the same schedule as for the corresponding prognostic groups of NSGCT (Grade of recommendation: A). In stage IIIB, chemotherapy with three cycles of standard-dose bleomycin, etoposide, and cisplatin (BEP), or four cycles of etoposide (EP), represents a treatment alternative to radiotherapy, but may be associated with a higher risk of acute toxicity as compared to radiotherapy.
6. Seminoma Stage IIC and higher should be treated with primary chemotherapy according to the same principles used for NSGCT (Grade of recommendation: A).
9. FOLLOW-UP AFTER CURATIVE THERAPY

9.1 General considerations
The selection of the test to be performed in follow-up should adhere to the following principles (249):

A The interval between examinations and duration of testing should be consistent with the time of maximal risk of recurrence and the natural history of the tumour.

B The tests should be directed at the most likely sites of recurrence and should have a high predictive value, both positive and negative.

C Therapy should be available that will result in cure of the recurrence, significant prolongation of life or palliation of symptoms. The initiation of earlier therapy should improve the outcome compared with therapy given when the patient becomes symptomatic from the tumour recurrence.

D The increased risk of second malignancy, both in the primary site and in other tissues that may have been exposed to the same carcinogens, or in which there is epidemiological evidence of increased risk, should also guide the ordering tests. Malignant and non-malignant complications of therapy must also be considered. Such testing should also be performed with a frequency and duration consistent with the nature of the risk and include only tests with high positive- and negative-predictive values.

The following considerations apply in a general manner for the selection of an appropriate schedule and testing in the follow-up of all stages of testis tumour:

- Most recurrences after curative therapy will occur in the first 2 years; consequently surveillance should be most frequent and intensive during this time.
- Late relapses can occur beyond 5 years and therefore yearly follow-up for life may be advocated.
- After RPLND, relapse in the retroperitoneum is rare; the most likely site of recurrence being the chest.
- The value of chest X-ray has been recently questioned in the follow-up of patients with disseminated disease after complete remission (250,251).
- CT of the chest has a higher predictive value than chest X-ray (251).
- The results of therapy are dependent on the bulk of disease; thus an intensive strategy to detect asymptomatic disease may be justifiable.
- After chemotherapy or radiotherapy, a long-term risk for secondary malignancies development exists.

9.2 Follow-up stage I non-seminoma
Approximately 5% of patients with clinical stage I NSGCT present with elevated levels of tumour markers after orchidectomy and up to 25-30% relapse during the first 2 years (5,112,129,132,151,252-255).

The follow-up schedule will differ depending on which of the three possible treatment strategies was chosen:

- Surveillance
- Nerve-sparing retroperitoneal lymphadenectomy (RPLND)
- Adjuvant chemotherapy.

9.2.1 Follow-up investigations during surveillance
The results of a surveillance policy depend upon a careful pre-operative staging procedure and follow-up management. In a ‘wait and see’ policy, relapses will occur in 30% of cases. Of these relapses, 80% will occur in the first 12 months after orchidectomy and approximately 12% during the second year. The median time to relapse is 6 months (range 1-62 months), but relapses after 3-5 years, and even later, may still occur, with an annual rate of 4% (107,108). Relapse occurs mainly in the retroperitoneum; approximately 20% of patients have evident metastases in the retroperitoneum and 10% in the mediastinum and lungs (256). Sometimes the only indication is an elevated level of tumour markers.

A randomized trial of two versus five CT scans has been published by the MRC recommending the reduction of imaging during surveillance in this stage to one CT scan at 3 months after orchidectomy and another one at 12 months. The trial with 414 patients was powered to exclude a 3% probability of detecting a patient during surveillance only, with a relapse presenting already-metastatic disease with ‘intermediate’ or ‘poor’ prognosis features. Relapses were detected in 15% with two CTs and 20% with five CTs; 1.6% of these patients had ‘intermediate’ or ‘poor’ prognosis features. Only 10% of patients had high-risk features (vascular invasion). In summary, this first randomized trial yields level 1 evidence for a minimum follow-up in patients with clinical stage I non-seminoma (121). The recommended follow-up schedule (Table 7) includes the minimum requirements for imaging and adds recommendations for other surveillance tests.
Table 7: Recommended minimum follow-up schedule in a surveillance policy: stage I non-seminoma

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Year</th>
<th>1</th>
<th>2</th>
<th>3-5</th>
<th>6-10</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical examination</td>
<td>3-monthly</td>
<td>3-monthly</td>
<td>Twice/year</td>
<td>Once/year</td>
<td></td>
</tr>
<tr>
<td>Tumour markers</td>
<td>3-monthly</td>
<td>3-monthly</td>
<td>Twice/year</td>
<td>Once/year</td>
<td></td>
</tr>
<tr>
<td>Chest X-ray</td>
<td>Twice/year</td>
<td>Twice/year</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abdominopelvic CT scan</td>
<td>Twice/year</td>
<td>(at 3 and 12 months)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CT = computed tomography scan.

9.2.2 Follow-up after nerve-sparing RPLND
Retroperitoneal relapse after a properly performed nerve-sparing RPLND is rare. RPLND should eliminate the retroperitoneal nodes as a site of relapse and thus the need for repeated abdominal CT scans. The USA Intergroup data show retroperitoneal relapse in 7/264 patients with pathological stage I disease (and 20 pulmonary relapses); four of these seven had no marker elevation (257). In the Indiana series, only one relapse in 559 cases was reported (258). If a relapse occurs, it is generally in the chest, neck or at the margins of the surgical field. Pulmonary relapses occur in 10-12% of patients and more than 90% of those relapses occur within 2 years of RPLND (73,259). However, the low rate of retroperitoneal relapse after RPLND can only be achieved by surgery in specialized centres as shown by the high in-field relapse rate (7 of 13 relapses) in the German randomized trial of RPLND versus one course of PEB (141). The recommended minimum follow-up schedule is shown in Table 8.

Table 8: Recommended minimum follow-up schedule after retroperitoneal lymphadenectomy or adjuvant chemotherapy: stage I non-seminoma

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Year</th>
<th>1</th>
<th>2</th>
<th>3-5</th>
<th>5-10</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical examination</td>
<td>3-monthly</td>
<td>3-monthly</td>
<td>Twice/year</td>
<td>Once/year</td>
<td></td>
</tr>
<tr>
<td>Tumour markers</td>
<td>3-monthly</td>
<td>3-monthly</td>
<td>Twice/year</td>
<td>Once/year</td>
<td></td>
</tr>
<tr>
<td>Chest X-ray</td>
<td>Twice/year</td>
<td>Twice/year</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abdominopelvic CT scan</td>
<td>Once/year</td>
<td>Once/year</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

CT = computed tomography scan.

9.2.3 Follow-up after adjuvant chemotherapy
Prospective reports with long-term follow-up after adjuvant chemotherapy have shown a low relapse rate (112,113,252,253) of about 3%. In a randomized trial with one course of PEB versus RPLND, the relapse rate with adjuvant chemotherapy was 1% (2 of 174 patients, one with marker relapse, one with mature teratoma in the retroperitoneum) (141). The need for repeated and long-term assessment of the retroperitoneum is still not clear. Owing to the risk of developing a late, slow-growing teratoma in the retroperitoneum after adjuvant chemotherapy, an abdominal CT should still be performed (see Table 8).

9.3 Follow-up stage I seminoma
The majority of patients with seminoma (70-80%) present with clinical stage I disease at diagnosis (88). In 15-20% of cases, there is nodal radiological involvement at the level of the retroperitoneum and only 5% of patients present with distant metastasis (88).

The relapse rate varies between 1% and 20%, depending on the post-orchidectomy therapy chosen. Only up to 30% of seminomas present with elevation of hCG at diagnosis or in the course of the disease. Consequently, in most cases, measurement of blood markers will not be a reliable test for follow-up (260). The treatment options post-orchidectomy in stage I seminoma are retroperitoneal radiotherapy, surveillance and adjuvant chemotherapy. Due to extreme radio- and chemosensitivity, high cure rates of almost 100% are reached with each of the approaches, even in case of relapse. The costs of the different therapies vary, as do the expected side effects (90,261,262).
9.3.1 Follow-up after radiotherapy
Low doses of radiotherapy (20-24 Gy) limited to the retroperitoneal or the hockey-stick field achieve an overall survival rate of approximately 99% at 5-10 years (98-100,263,264). The rate of relapse is 1-2% and the most common time of presentation is within 18 months after treatment (98,101,262,265,266), although late relapses have also been described (267). The site of relapse is mainly at the supradiaphragmatic lymph nodes, mediastinum, lungs or bones. In a small proportion of cases, the tumour will relapse in the inguinal or external iliac nodes (88).

The side effects of radiotherapy include impaired spermatogenesis, gastrointestinal symptoms (peptic ulceration) and induction of second malignancies (262,268,269). Up to 50% of patients can develop moderate toxicity grade I-II (263). The schedule of follow-up is described in Table 9.

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Year</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4–5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical examination</td>
<td></td>
<td>3-monthly</td>
<td>3-monthly</td>
<td>Twice/year</td>
<td>Once/year</td>
</tr>
<tr>
<td>Tumour markers</td>
<td></td>
<td>3-monthly</td>
<td>3-monthly</td>
<td>Twice/year</td>
<td>Once/year</td>
</tr>
<tr>
<td>Chest X-ray</td>
<td></td>
<td>Twice/year</td>
<td>Twice/year</td>
<td>Once/year</td>
<td>Once/year</td>
</tr>
<tr>
<td>Abdominopelvic CT scan</td>
<td></td>
<td>Twice/year</td>
<td>Twice/year</td>
<td>Once/year</td>
<td>Once/year</td>
</tr>
</tbody>
</table>

CT = computed tomography scan.

9.3.2 Follow-up during surveillance
The actuarial risk of relapse at 5 years ranges between 6% (low risk) and 20% (95,270-274). There is no increased risk of death. The median time to relapse ranges from 12-18 months, but up to 29% of relapses can develop later (88,275). The sites of relapse are the PA lymph nodes in up to 82% of cases; the pelvic lymph nodes, inguinal nodes and lungs can also be affected (88,276-280). Due to the high and often late rate of relapse, close and active follow-up is mandatory for at least 5 years (281) (see Table 9).

9.3.3 Follow-up after adjuvant chemotherapy
One or two courses of carboplatin-based chemotherapy is an effective alternative treatment in stage I seminoma. The relapse rate is 1.9-4.5%. In general, this treatment is well tolerated, with only mild, acute and intermediate-term toxicity (282,283). Long-term data on late relapses and survival are missing (see Table 9).

9.4 Follow-up stage II and advanced (metastatic) disease
The more advanced the nodal stage of the disease, the higher the likelihood of recurrence (136). In general, the primary tumour bulk governs the outcome for patients with NSGCT (284). In stage II NSGCT, regardless of the treatment policy adopted, excellent survival rates of 97% are reached, provided that relapse is identified as soon as possible (146,147,152).

In advanced metastatic germ cell tumours, the extent of the disease is correlated with the response to therapy and with survival. The combination of cisplatin-based chemotherapy and surgery (aggressive multimodality) achieves cure rates between 65% and 85%, depending on the initial extent of disease (284,285). Complete response rates to chemotherapy are in the order of 50-60% (284); another 20-30% of patients could be rendered disease-free with post-chemotherapy surgery (286).

The main reasons for failure of therapy in advanced NSGCT are (284,287,288):
- The presence of bulky disease not responding completely to chemotherapy
- Unresectable residual teratoma after chemotherapy
- Presence or development of chemoresistant non-germ elements, which account for 8.2% of cases.

Table 9: Recommended minimum follow-up schedule for post-orchiectomy surveillance, radiotherapy or chemotherapy: stage I seminoma

The update as of March 2008.
Table 10: Recommended minimum follow-up schedule in advanced NSGCT and seminoma

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Year 1</th>
<th>Year 2</th>
<th>Year 3-5</th>
<th>Thereafter</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical Examination</td>
<td>3-monthly</td>
<td>3-monthly</td>
<td>Twice/year</td>
<td>Once/year</td>
</tr>
<tr>
<td>Tumour Markers</td>
<td>3-monthly</td>
<td>3-monthly</td>
<td>Twice/year</td>
<td>Once/year</td>
</tr>
<tr>
<td>Chest X-ray</td>
<td>3-monthly</td>
<td>3-monthly</td>
<td>Twice/year</td>
<td>Once/year</td>
</tr>
<tr>
<td>Abdominopelvic CT scan</td>
<td>Twice/year</td>
<td>Twice/year</td>
<td>Once/year</td>
<td>Once/year</td>
</tr>
<tr>
<td>Chest CT</td>
<td>As indicated</td>
<td>As indicated</td>
<td>As indicated</td>
<td>As indicated</td>
</tr>
<tr>
<td>Brain CT</td>
<td>As indicated</td>
<td>As indicated</td>
<td>As indicated</td>
<td>As indicated</td>
</tr>
</tbody>
</table>

CT = computed tomography scan.

- Abdominal CT scanning has to be performed at least annually if teratoma is found in the retroperitoneum.
- If the post-chemotherapy evaluation shows any mass >3 cm, the appropriate CT scan should be repeated 2 and 4 months later to ensure that the mass is continuing to regress. If available, FDG-PET scanning can be performed.
- A chest CT is indicated if abnormality is detected on chest X-ray and after pulmonary resection.
- In patients with headaches, focal neurological findings or any central nervous system symptom.

10. TESTICULAR STROMAL TUMOURS

10.1 Background
Testicular stromal tumours are rare and account for only 2-4% of adult testicular tumours. However, only Leydig cell and Sertoli cell tumours are of clinical relevance. As no general recommendations are published to date, the Testicular Cancer Working Group of the European Association of Urology (EAU) has decided to include these tumours in the EAU Germ Cell Tumour Guidelines. Recommendations for diagnosis and treatment are given only for Leydig and Sertoli cell tumours.

10.2 Methods
A Medline search for Leydig cell tumours (synonym: interstitial cell tumour) and Sertoli cell tumours (synonym: androblastoma) was performed. Approximately 850 papers were found. After excluding pure laboratory work without clinical data, female and paediatric tumours and animal cases, 371 papers and abstracts were reviewed. Double publications and papers with unclear histology or missing data on clinical course were excluded. The majority of the remaining 285 publications are case reports, with only a few papers reporting series of more than 10 cases, most of them published in the pathology literature. The true incidence of stromal tumours remains therefore uncertain and the proportion of metastatic tumours can only be given approximately.

Nevertheless, the symptoms for pre-operative suspicion of testicular stromal tumours and the characteristics of tumours at high risk for metastases are sufficiently well established (EBM IIA and EBM IIB) to enable recommendations to be made regarding diagnosis and surgical approach. However, no recommendations for appropriate follow-up can be given due to the absence of follow-up data in most reported cases and the fatal outcome of metastatic tumours, irrespective of the therapy chosen.

The individual publications have been rated according to EBM categories (see above).

The literature research for clinical data on Leydig cell tumours resulted in 193 publications dealing with more than 480 tumours in adults, including three publications (1-3) reporting larger series on a total of 90 patients. Follow-up data of more than 2 years are available for about 80 patients.

The literature research for clinical data on Sertoli cell tumours resulted in 93 publications dealing with more than 260 tumours in adults, including three publications (from the same group) (4-6) reporting on a total of 80 patients. Follow-up data of more than 2 years are available in less than 40 patients.

10.3 Classification
The non-germ cell tumours of the testicle include the sex cord/gonadal stromal tumours and the miscellaneous
non-specific stromal tumours. The different histological subtypes of testicular tumours are defined according to the WHO classification 2004 (adapted) (7).

10.4 Leydig cell tumours

10.4.1 Epidemiology

Leydig cell tumours constitute about 1-3% of adult testicular tumours (2,8) and 3% of testicular tumours in infants and children (8). The tumour is most common in the third to sixth decade in adults with a similar incidence observed in every decade. Another peak incidence is seen in children between 3 and 9 years. Three percent of Leydig cell tumours are bilateral (2). Occasionally, they occur in patients with Klinefelter syndrome (8).

10.4.2 Pathology of Leydig cell tumours

Leydig cell tumours are the most common type of sex cord/gonadal stromal tumours. Histopathologically, they are well outlined and usually up to 5 cm in diameter. They are also solid, coloured yellow to tan, with haemorrhage and/or necrosis present in 30% of cases. Microscopically, the cells are polygonal, with eosinophilic cytoplasm with occasional Reinke crystals, regular nucleus, solid arrangement and capillary stroma. The cells express vimentin, inhibin, protein S100, steroid hormones, calretinin and cytokeratin (focally) (7).

About 10% of Leydig cell tumours are malignant tumours, which present with the following parameters:

- Large size (> 5 cm)
- Cytological atypia
- Increased mitotic activity (> 3 per 10 high-power field [HPF])
- Increased MIB-1 expression (18.6% vs 1.2% in benign)
- Necrosis
- Vascular invasion (9)
- Infiltrative margins
- Extension beyond the testicular parenchyma
- DNA aneuploidy (1,10).

10.4.3 Diagnosis

Patients either present with a painless enlarged testis or the tumour is an incidental ultrasound finding. In up to 80%, hormonal disorders with high oestrogen and oestradiol levels and low testosterone, increased levels of LH and FSH are reported (11,12), while negative results are always obtained for the testicular germ cell tumour-markers, AFP, hCG, LDH and PLAP. Approximately 30% of patients present with gynaecomastia (13,14). Three percent of tumours are bilateral (2). Leydig cell tumours must be distinguished from the multinodular tumour-like and often bilaterally occurring lesions of the androgenital syndrome (15).

Diagnostic work-up must include markers, hormones (at least testosterone, LH and FSH; if not conclusive, additionally, oestrogen, oestradiol, progesterone and cortisol), ultrasound of both testes and CT scan of chest and abdomen. On ultrasound, it may be possible to observe well-defined, small, hypoechoic lesions with hypervascularization, but the appearance is variable and is indistinguishable from germ cell tumours (16,17).

The proportion of metastatic tumours in all published case reports is only 10%. Within three larger series with longer follow-up, 18 metastatic tumours were found in a total of 83 cases (21.7%) (1-3). Histopathological signs of malignancy have been depicted above (see 4.2) (1,10). In addition, patients of older age have a greater risk of harbouring a tumour of malignant potential.

10.4.4 Treatment

Asymptomatic testicular tumours of small volume are often misinterpreted as germ cell tumours and inguinal orchidectomy is performed. It is highly recommended to perform an organ-sparing procedure in every small intraparenchymal lesion to gain the histological diagnosis. Especially in patients with symptoms of gynaecomastia or hormonal disorders, a non germ-cell tumour should be considered and immediate orchidectomy should be avoided (18). In cases of germ cell tumour in either frozen section or paraffin histology, orchidectomy is recommended as long as a contralateral normal testicle is present.

In stromal tumours with histological signs of malignancy, especially in patients of older age, orchidectomy and retroperitoneal lymphadenectomy is recommended to prevent metastases (19). Without histological signs of malignancy, an individualized surveillance strategy after orchidectomy is recommended (CT follow-up may be most appropriate since specific tumour markers are not available).
Tumours that have metastasized to lymph nodes, lung, liver or bone respond poorly to chemotherapy or radiation and survival is poor (19).

10.4.5 Follow-up
Recommendations for appropriate follow-up cannot be given because of the lack of follow-up data in most reported cases and the lethal outcome of metastatic tumours, irrespective of the therapy chosen.

10.5 Sertoli cell tumour
10.5.1 Epidemiology
Sertoli cell tumours account for less than 1% of testicular tumours and the mean age at diagnosis is around 45 years, with rare cases under 20 years of age (4,20). On rare occasions, these tumours may develop in patients with the androgen insensitivity syndrome and Peutz-Jeghers syndrome.

10.5.2 Pathology of Sertoli cell tumours
The tumour is well circumscribed, yellow, tan or white, with an average diameter of 3.5 cm (4). Microscopically, the cells are eosinophilic to pale with vacuolated cytoplasm. The nuclei are regular with grooves and there may be inclusions. The arrangement of the cells is tubular or solid; a cord-like or retiform pattern is possible. The stroma is fine and capillary, but in some cases a sclerosing aspect predominates. The cells express vimentin, cytokeratins, inhibin (40%) and protein S-100 (30%) (4).

The rate of malignant tumours ranges between 10% and 22% and less than 50 cases are reported (23-25). Signs of a malignant Sertoli tumour are:
- Large size (> 5 cm)
- Pleomorphic nuclei with nucleoli
- Increased mitotic activity (> 5 per 10 hpf)
- Necrosis, and
- Vascular invasion.

10.5.2.1 Classification
Three subtypes have been described (20):
- The classic Sertoli cell tumour (4)
- The large cell calcifying form with characteristic calcifications (5,21)
- The rare sclerosing form (6,22).

10.5.3 Diagnosis
Patients present either with an enlarged testis or the tumour is an incidental ultrasound finding (26). Most classic Sertoli tumours are unilateral and unifocal. Hormonal disorders are infrequent, though gynaecomastia is sometimes seen (4). The testicular tumour-markers, AFP, hCG, LDH and PLAP are always negative.

Diagnostic work-up has to include tumour markers, hormones (at least testosterone, LH and FSH; if not conclusive, additionally, oestrogen, oestradiol, progesterone and cortisol), ultrasound of both testes and CT scan of chest and abdomen.

Sertoli cell tumours are generally hypoechoic on ultrasound but they can be of variant appearance and therefore cannot be safely distinguished from germ cell tumours (20). Only the large cell calcifying form has a characteristic image with brightly echogenic foci due to calcification (27,28).

The large cell calcifying form is diagnosed in younger men and is associated with genetic syndromes (Carney’s complex (29) and Peutz-Jeghers syndrome (30)) or, in about 40% of cases, endocrine disorders. Forty-four percent of cases are bilateral, either synchronous or metachronous, and 28% show multifocality (24).

The characteristics of metastatic tumours have been depicted above (24,25). However, among patients whose tumours have been histopathologically classified as ‘malignant’ using these or similar characteristics (i.e. 18.8% of tumours in all reported cases), only 7% showed metastatic disease during follow-up.

In the largest series with the longest follow-up, 7.5% of patients had been classified as ‘malignant’ at primary diagnosis and 11.7% showed metastatic disease long-term (4). In general, affected patients are of higher age, tumours are nearly always palpable and show more than one sign of malignancy (4).

Up to 20% of the large cell sclerosing form are malignant. There are some hints that discrimination between an
early and late onset type may define a different risk for metastatic disease (5.5% compared with 23%) (20). Metastases in the infrequent sclerosing subtype are rare.

10.5.4 Treatment
Testicular tumours of small volume, otherwise asymptomatic, are often misinterpreted as germ cell tumours and inguinal orchidectomy is performed. It is highly recommended to proceed with an organ-sparing approach in small intraparenchymal testicular lesions until final histology is available. Especially, in patients with symptoms of gynaecomastia or hormonal disorders or typical imaging on ultrasound (calcifications, small circumscribed tumours), organ-sparing surgery should be considered. Secondary orchidectomy can be performed if final pathology reveals a non-stromal (e.g. germ cell) tumour. Organ-sparing surgical approaches are justified as long as the remaining testicular parenchyma is sufficient for endocrine (and in stromal tumours also exocrine) function.

In tumours with histological signs of malignancy, especially in patients of older age, orchidectomy and retroperitoneal lymphadenectomy are recommended to prevent metastases (19). Without signs of malignancy, an individualized surveillance strategy after orchidectomy is recommended (CT scans may be most appropriate since specific tumour-markers are not available). Tumours metastasizing to lymph nodes, lung or bone respond poorly to chemotherapy or radiation and survival is poor.

10.5.5 Follow-up
Recommendations for appropriate follow-up cannot be given because of the lack of follow-up data in most reported cases and the lethal outcome of metastatic tumours, irrespective of the therapy chosen.

10.6 Granulosa cell tumour
This is a rare tumour, with two variants - juvenile and adult:

- The juvenile type is benign. It is the most frequent congenital testicle tumour and represents 6.6% of all prepuberal testicular neoplasms. The cystic appearance is characteristic of this tumour type (31).
- With the adult type, the average age at presentation is 44 years. The typical morphology is of a homogeneous, yellow-grey, tumour, with elongated cells, with grooves in micro-follicular and Call-Exner bodies’ arrangement.

Malignant tumours represent around 20% of cases. They are usually > 7 cm diameter. Vascular invasion and necrosis are features suggestive of malignant biology (32).

10.7 Thecoma/fibroma group of tumours
These tumours are very rare and benign (7).

10.8 Other sex cord/gonadal stromal tumours
Sex cord/gonadal stromal tumours may be incompletely differentiated or mixed forms.

There is limited experience with incompletely differentiated sex cord/gonadal stromal tumours and no cases of reported metastasis (7). In mixed tumour forms, all the histological components should be reported. However, the clinical behaviour is most likely to reflect the predominant pattern or the most aggressive component of the tumour (33).

10.9 Tumours containing germ cell and sex cord/gonadal stromal (gonadoblastoma)
If the arrangement of the germ cells are in nested pattern and the rest of the tumour is composed of sex cord/gonadal stroma, the term gonadoblastoma is used. It is most frequent in gonadal dysgenesis with ambiguous genitalia. Bilateral tumours are present in 40% of cases. The prognosis is correlated with the invasive growth of the germinal component (34).

In the case of a diffuse arrangement of the different components, there are some doubts about the neoplastic nature of the germinal cells and some authors consider them to be entrapped rather than neoplastic (35).

10.10 Miscellaneous tumours of the testis
10.10.1 Tumours of ovarian epithelial types
These tumours resemble the epithelial tumours of the ovary. Cystic appearance with occasional mucinous material can be observed. Microscopically, the aspect is identical to their ovarian counterparts and their evolution is similar to the different epithelial ovarian subtypes. Some Brenner types can be malignant (7).
10.10.2 Tumours of the collecting ducts and rete testis
These tumours are very rare. Benign (adenoma) and malignant (adenocarcinoma) have been reported, with malignant tumours showing local growth with a mortality rate of 56% (18).

10.10.3 Tumours (benign and malignant) of non-specific stroma
These are very uncommon and have a similar criteria, prognosis and treatment as the soft tissue sarcomas.

11 REFERENCES

11.1 References germ cell tumours

UPDATE MARCH 2008


UPDATE MARCH 2008


UPDATE MARCH 2008 35


UPDATE MARCH 2008


http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=40&abstractID=30203


UPDATE MARCH 2008


UPDATE MARCH 2008


UPDATE MARCH 2008 45


11.2 NON-GERM CELL TUMOURS


8. Ulbright TM, Amin MB, Young RH. Tumours of the testis, adnexia, spermatic cord and scrotum. AFIP 1999. EBM III.


### 12. ABBREVIATIONS USED IN THE TEXT

This list is not comprehensive for the most common abbreviations.

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Meaning</th>
</tr>
</thead>
<tbody>
<tr>
<td>AFP</td>
<td>alpha-fetoprotein</td>
</tr>
<tr>
<td>AUC</td>
<td>area under curve</td>
</tr>
<tr>
<td>hCG</td>
<td>human chorionic gonadotrophin</td>
</tr>
<tr>
<td>Cg A</td>
<td>chromogranine A</td>
</tr>
<tr>
<td>CI</td>
<td>confidence interval</td>
</tr>
<tr>
<td>CS</td>
<td>clinical stage</td>
</tr>
<tr>
<td>CT</td>
<td>computed tomography</td>
</tr>
<tr>
<td>EBM</td>
<td>evidence-based medicine</td>
</tr>
<tr>
<td>EP</td>
<td>etoposide, cisplatin</td>
</tr>
<tr>
<td>EORTC</td>
<td>European Organization for Research and Treatment of Cancer</td>
</tr>
<tr>
<td>FDG-PET</td>
<td>fluorodeoxyglucose-positron-emission tomography</td>
</tr>
<tr>
<td>FSH</td>
<td>follicle-stimulating hormone</td>
</tr>
<tr>
<td>GI</td>
<td>chronic gastrointestinal</td>
</tr>
<tr>
<td>G-CSF</td>
<td>granulocyte colony-stimulating factor</td>
</tr>
<tr>
<td>HPF</td>
<td>high power field</td>
</tr>
<tr>
<td>IGCCCG</td>
<td>International Germ Cell Cancer Collaborative Group</td>
</tr>
<tr>
<td>LH</td>
<td>luteinizing hormone</td>
</tr>
<tr>
<td>LDH</td>
<td>lactate dehydrogenase</td>
</tr>
<tr>
<td>MRC</td>
<td>Medical Research Council</td>
</tr>
<tr>
<td>MRI</td>
<td>magnetic resonance imaging</td>
</tr>
<tr>
<td>NSGCT</td>
<td>non-seminomatous germ cell tumour</td>
</tr>
<tr>
<td>PA</td>
<td>para-aortic</td>
</tr>
<tr>
<td>PEB</td>
<td>cisplatin, etoposide, bleomycin</td>
</tr>
<tr>
<td>PEI</td>
<td>cisplatin, etoposide, ifosfamide</td>
</tr>
<tr>
<td>PET</td>
<td>positron emission tomography</td>
</tr>
<tr>
<td>PS</td>
<td>pathological stage</td>
</tr>
<tr>
<td>PVI</td>
<td>cisplatin, vinblastine, ifosfamide</td>
</tr>
<tr>
<td>PLAP</td>
<td>placental alkaline phosphatase</td>
</tr>
<tr>
<td>PVB</td>
<td>cisplatin, vinblastine, bleomycin</td>
</tr>
<tr>
<td>RPLND</td>
<td>retroperitoneal lymph node dissection</td>
</tr>
<tr>
<td>Tin</td>
<td>intratubular germ cell neoplasia</td>
</tr>
<tr>
<td>TIP</td>
<td>paclataxel, ifosmamide, cisplatin</td>
</tr>
<tr>
<td>TNM</td>
<td>Tumour Node Metastasis</td>
</tr>
<tr>
<td>UIICC</td>
<td>International Union Against Cancer</td>
</tr>
<tr>
<td>VAB</td>
<td>vinblastine, Adriamycin, bleomycin</td>
</tr>
<tr>
<td>VelP</td>
<td>velban, ifosfamide, cisplatin</td>
</tr>
<tr>
<td>WHO</td>
<td>World Health Organisation</td>
</tr>
<tr>
<td>VIP (VP-16)</td>
<td>vinblastine, ifosfamide, cisplatin</td>
</tr>
</tbody>
</table>

**Conflict of interest**

All members of the Testicular Cancer guidelines writing panel have provided disclosure statements of all relationships which they have and which may be perceived as a potential source of conflict of interest. This information is kept on file in the European Association of Urology Central Office database. This guidelines document was developed with the financial support of the European Association of Urology. No external sources of funding and support have been involved.